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Summary 
Background 
Approximately a third of women receiving pethidine for labour pain subsequently require an epidural, which 
provides effective pain relief but increases the risk of instrumental delivery. Remifentanil patient controlled 
analgesia (PCA) in labour is an alternative to pethidine, but not widely utilized. We sought to determine epidural 
rates amongst women using remifentanil PCA compared to pethidine.  
Methods 
We conducted a randomised, parallel, open-label trial in 14 UK maternity units. Women at term gestation, in 
labour with a singleton cephalic presentation, requesting opioid pain relief, were randomly assigned (1:1) to 
remifentanil PCA (40µg bolus with a two minute “lock-out”) or intramuscular pethidine (100mg, four-hourly, 
up to 400mg). Web-based or telephone randomisation minimised allocations by parity, age, ethnicity and mode 
of labour onset. The primary outcome was the proportion of women who received epidural analgesia after 
enrolment.  To detect a reduction in epidural conversion from 30% to 15% with 90% power, with a 15% 
anticipated attrition from urgent delivery by emergency caesarean section, required 400 women. Primary 
analyses were unadjusted and by intention-to-treat. ISRCTN29654603. 
Findings 
Between May 2014 and September 2016, 201 women were randomised to remifentanil PCA and 200 to 
pethidine. Epidural conversion rates were 19% (39/201) and 41% (81/199) respectively (RR 0·48, 95% CI 0·34 
to 0·66, P<0·0001).  
Interpretation 
Remifentanil intravenous PCA halves epidural conversion rates compared to intramuscular pethidine.  These 
findings challenge routine pethidine use as standard care in labour. 
Funding 
NIHR Clinician Scientist award. 
 
 
 
 
 
 
Research in context 
Evidence before this study 
The Cochrane review on Patient-controlled analgesia with remifentanil versus alternative parenteral methods for 
pain management in labour was published in April 2017.  It separately meta-analysed comparisons with 
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remifentanil according to whether pethidine was administered IM/IV or by PCA. Three studies with 190 
participants for the outcome ‘additional analgesia required’ showed a reduction for remifentanil compared to 
IM/IV pethidine (RR 0·57, 95% CI 0·40-0·81) and no difference in three studies with 215 participants for PCA 
pethidine (RR 0·76 95% CI 0·45 to1·28).  In all but one study, the additional analgesia was epidural.  None of 
the studies in these reviews were designed to examine epidural conversion as a primary outcome. The Cochrane 
review concluded that the evidence was too low in quality to inform practice and that future research was 
needed including data on potential maternal and neonatal side effects. Prior to the RESPITE trial being 
designed, our searches had found four small, heterogeneous trials comparing remifentanil with pethidine for 
labour analgesia (see original protocol).  A systematic review published in 2012, before RESPITE commenced 
recruitment, showed a reduction in progression to epidural with remifentanil compared to pethidine 
administered by various routes from four poor quality studies (n=244 women) (RR 0·34, 95% CI 0·2-0·58).   
 
Added value of this study 
This study has provided conclusive evidence of the benefit of remifentanil PCA for women in labour, relative to 
intramuscular pethidine.  It is the first randomised controlled trial conducted with sufficient rigor to inform 
practice.   The requirement for epidural pain relief was halved in women who received remifentanil in 
comparison to pethidine.  Epidural conversion rates were 19% (39/201) and 41% (81/199) respectively (RR 
0·48, 95% CI 0·34 to 0·66, P<0·0001). Women randomised to remifentanil PCA were less likely to require 
instrumental vaginal delivery (15% vs 26%); RR 0.59 (95% CI 0.40 to 0.88, p=0.008). A reduction in 
instrumental delivery has the potential to accrue long-term benefit by avoiding associated morbidity.  There was 
a greater requirement for supplemental maternal oxygen with remifentanil PCA, relative to intramuscular 
pethidine, although we found that it was not uniformly required. Maternal side effects were transient, easily 
recognised and managed and no neonatal effects were detected.  This study is unique in examining epidural 
“rescue” as a primary outcome, reporting neonatal resuscitation requirement at birth and maternal satisfaction 
with pain relief. 
 
Implications of all the available evidence 
The high quality evidence from RESPITE is consistent with prior low quality data that the rate of epidural 
rescue analgesia is halved, in women requesting opioid pain relief in labour with remifentanil PCA compared 
with IM pethidine.  If the evidence from the studies included in the recent Cochrane Review and the results of 
RESPITE are considered together, the pooled risk ratio of a requirement for “rescue” analgesia with 
remifentanil, relative to pethidine yielded is 0·54, (95% CI 0·42 to 0·68).  In the 3 studies included in the 
Cochrane review to generate this comparison, epidural was a possible rescue in two trials with further pethidine 
or Entonox in one. Our study demonstrated no excess risk of maternal respiratory depression or adverse foetal 
outcomes with remifentanil, relative to pethidine.  The use of remifentanil PCA as a “first line” opioid for pain 
relief in labour in preference to pethidine would reduce epidural rates, instrumental delivery and consequent 
morbidity for large numbers of women worldwide. The implications are that a fundamental re-evaluation of 
opioid pain relief in labour is required, challenging the routine use of pethidine in childbirth.  
Introduction 
Childbirth can be extremely painful and the provision of effective pain relief during labour is a vital element of a 
positive maternal experience. More than a quarter of a million women per year in the UK receive the opioid 
drug pethidine by intramuscular (IM) injection, and many more worldwide
1
. Despite widespread international 
use, pethidine is not uniformly effective in relieving labour pain
2
 and has proven side effects including maternal 
sedation, nausea and potential transfer across the placenta to the foetus
3
. More than a third of women who 
receive pethidine subsequently require an epidural
4
 for pain relief.  Epidural analgesia is the most effective form 
of pain relief in labour and is associated with high levels of maternal satisfaction, however there is an increased 
likelihood of instrumental vaginal delivery (IVD) and prolongation of the second stage of labour
5, 6
. This impact 
is reduced by modern “low-dose” epidural techniques, but not completely mitigated5. IVD is associated with 
perineal trauma and long term morbidity thereafter, such as faecal incontinence
7
 and sexual dysfunction
8, 9
. 
4 
 
Remifentanil is a potent synthetic opioid with novel pharmacokinetic properties, including very rapid onset and 
ultra-short duration of action, making it effective for pain relief in labour when administered by intravenous 
patient controlled analgesia (PCA) and thus a potential alternative to pethidine. However, most maternity units 
in the UK rarely use remifentanil PCA in routine practice
10
, restricting it to circumstances when epidural 
analgesia is contraindicated. This pattern of use is similar in other European countries
11
. The main reasons for 
this limited use is the paucity of high quality evidence for its benefit, relative to pethidine as the traditional 
opioid used in labour and concerns regarding the potential for opioid induced maternal respiratory depression
12
. 
A Cochrane review evaluating remifentanil PCA relative to a range of other methods of labour pain 
management
13
 reported remifentanil compared to intramuscular pethidine in three trials
14-16
, to intravenous 
pethidine in one trial
4
 and to PCA pethidine in three trials
17-19
 but concluded that all these studies provided low 
quality evidence, limited by inconsistency and imprecision, and that more robust research was needed to 
evaluate possible maternal and foetal effects . 
The aim of the RESPITE trial was to compare two “policies” of opioid pain relief in labour; intravenous 
remifentanil PCA with intra-muscular pethidine injection, to determine whether remifentanil PCA reduced 
progression to epidural analgesia and evaluate if it resulted in any adverse maternal or neonatal sequelae
20, 21
.  
 
Methods 
Study design and participants 
RESPITE was a two-group, parallel, randomised, open-label, multi-centre trial, conducted in 14 obstetric-led 
maternity units in the UK. Units were able to participate in RESPITE if intramuscular pethidine was the 
standard care for pain relief in childbirth.  The study established a care pathway that allowed eligible women to 
promptly receive intravenous remifentanil PCA, however it was not routinely available, on maternal request, at 
participating centres, outside the context of the study. 
Women, aged 16 years or over and beyond 37+0 weeks’ gestation, with a singleton live baby, in cephalic 
presentation, who were in established labour (defined as regular painful contractions irrespective of cervical 
dilatation), intending vaginal birth, were initially eligible and written informed consent was sought. All women 
booked for delivery at participating centres were informed about the study prior to labour at antenatal visits.  
Participants were eligible to consent in labour provided they had received information about the study 
beforehand.  Women were randomised when they requested systemic opioid analgesia, provided they had not 
received such analgesia in the preceding four hours, had no contraindications to remifentanil, pethidine or 
epidural analgesia and were not participating in any other drug trial. 
The trial had a favourable ethical opinion from the National Research Ethics Service Nottingham 2 Research 
Ethics Committee (reference: 13/EM0239). A Trial Steering Committee (TSC) provided independent oversight 
of the trial. Confidential interim analysis of all available data alongside anonymised reports of adverse events 
suffered by participants was reviewed by a Data Monitoring Committee (DMC) on three occasions. No reason 
to recommend halting or modifying the trial was identified.  The trial protocol has been published elsewhere
22
.  
Randomisation and masking 
Women were randomised to either intravenous remifentanil PCA or intramuscular pethidine in a 1:1 ratio, via a 
web-based central service or a 24/7 interactive telephone-based service. A minimisation algorithm was used to 
avoid chance imbalances in four variables: parity (nulliparous vs. multiparous), maternal age (<20, 20-<30, 30-
<40, ≥40 years), ethnicity (south Asian vs. other) and onset of labour (induced vs. spontaneous).  
Due to the differences in routes of drug administration and the fact that recipients of remifentanil became 
immediately aware of the drug’s effect and therefore of their group allocation, study participants and healthcare 
providers could not be masked to the intervention group. 
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Procedures 
Remifentanil was administered via a dedicated intravenous cannula. The patient controlled analgesia (PCA) 
pump was pre-programmed by physician anaesthetists, with a regime to provide a bolus of 40μg remifentanil on 
demand, with a “lockout” interval of two minutes.  This dose regime was based on sample guidelines adapted 
from those used in the introduction of remifentanil PCA into clinical practice in some UK labour wards and 
reflects those used in the largest study prior to the start of RESPITE
18
.  In the event of excess sedation being 
recorded by regular observation of sedation score and respiratory function, the regimen was reduced to 30µg 
with a lock-out interval of two minutes.  Pethidine was given by the attending midwife in a dose of 100mg, by 
intramuscular injection, up to four hourly in frequency, to a maximum dose of 400mg in 24 hours. 
Following administration of opioid analgesia, all women received one-to-one midwifery care, irrespective of 
study group allocation. Clinical observations were made every 30 minutes including recordings of respiratory 
rate and a numerical sedation score (1: Fully awake, 2: Drowsy, 3: Eyes closed, rousable by voice, 4: Eyes 
closed, rousable to physical stimulus, 5: Eyes closed, not rousable).  A visual analogue pain score (VAS) was 
recorded every 30 minutes from trial entry (0=no pain, to 100=worst pain imaginable). Pain scores were 
discontinued after epidural placement, delivery or transfer to theatre.  Maternal oxygen saturation was 
monitored continuously by pulse oximetry and recorded every 30 minutes. Saturations recorded <94% when 
breathing room air was the threshold for mandatory maternal oxygen supplementation. Indications for 
contacting a physician anaesthetist were excessive maternal sedation; score 4 or greater (not rousable to voice), 
a respiratory rate <8 breaths/minute or oxygen saturation <94% despite supplemental inspired oxygen therapy.   
Women were free to request epidural pain relief at any point after trial entry. Neither the consenting physicians, 
nor research midwives or nurses, were involved with a decision to proceed to epidural. A maternal request for 
epidural analgesia was treated according to local practice and administered according to individual labour ward 
protocols.  Once effective epidural pain relief was established, the administration of the study drugs was 
discontinued irrespective of group allocation.  Maternal visual analogue pain scores were discontinued after 
epidural analgesia. All data were collected prior to hospital discharge.  
Outcomes 
The primary outcome was the proportion of women who had an epidural placed for pain relief in labour after 
randomisation.  
Pre-specified secondary maternal outcomes were the effectiveness of pain relief, quantified by Visual Analogue 
Scale (where 0 was no pain and 100 was worst possible pain) taken every 30 minutes; delivery mode 
(spontaneous vaginal delivery, instrumental vaginal delivery and caesarean section); excessive sedation score  
4 (not rousable to voice); respiratory depression (respiratory rate <8 breaths/minute); oxygen saturation <94% 
whilst breathing room air; requirement for supplemental oxygen, anti-emetic administration and maternal 
satisfaction with pain relief, determined by postpartum questionnaire of childbirth experience, prior to hospital 
discharge. Pre-specified neonatal outcomes were the requirement for expedited interventional delivery to resolve 
foetal distress, persistent low Apgar score at five minutes (<4), foetal acidosis determined by umbilical cord gas 
analysis (if performed), the requirement for neonatal resuscitation, admission to neonatal special care and the 
rate of initiation of breast feeding within the first hour of birth.  
Statistical Analysis 
Epidural conversion rates after Remifentanil PCA were reported in a range of 5% to 19% in previous 
randomised trials,
4, 16-18
 compared to conversion rates of greater than 30% (range 17% to 39%) in women 
receiving pethidine. Taking a deliberately conservative estimate of intervention effect using these data, a 
reduction in epidural conversion from 30% (pethidine) to 15% (remifentanil PCA) was considered reasonable. 
To detect such a reduction with 90% power at α=0·05, required 161 women in each arm of the trial, yielding a 
sample size of 322 in total. Adjustment was made to account for attrition of the study population as labour 
progressed, anticipating that no more than 15% of the women would require urgent delivery, by emergency 
caesarean section before a request for further analgesia could be made.  Accounting for a modest unavailability 
of primary outcome data and non-adherence of 6%, a total sample size of 400 was required. 
6 
 
Demographic factors and clinical characteristics were summarised with counts (percentages) for categorical 
variables, mean (standard deviation) for normally distributed continuous variables, or median (interquartile 
range) for non-normal continuous variables. Treatment effects were presented as risk ratios or mean differences, 
with 95% confidence intervals (CI). 
The primary analysis was a comparison of the analgesic method assigned at randomisation (unadjusted 
intention-to-treat analysis).  Two sided tests were considered significant if p<0·05.  In addition to the primary 
unadjusted analysis, a log-binomial model was fitted to account for the minimisation variables. A pre-specified 
subgroup analysis was performed for parity.  
Two post-hoc sensitivity analyses were conducted to explore the impact of adherence to group allocation by trial 
participants.  The first included only those women who were fully adherent to their group allocation i.e. received 
at least one dose of the analgesic to which they were originally randomised and no dose of the alternative 
analgesic.  The second analysed women according to the analgesic they ultimately received.  
All analyses were performed in SAS version 9.4 (SAS Corporation, USA) 
There were no substantial changes to the main study protocol after recruitment commenced. The trial is 
registered at ISRCTN, number ISRCTN29654603. 
Role of funding source 
The funder of the study had no role in study design, data collection, data analysis, data interpretation, writing of 
the report, or decision to submit the results for publication. The corresponding author and trial statisticians had 
full access to all the data in the study. All authors in the writing team shared final responsibility for the decision 
to submit for publication. 
The manufacturers of analgesic pump equipment for remifentanil PCA used in the trial were not involved in any 
aspect of the study. Members of PRIME (Public and Researchers Involvement in Maternity and Early pregnancy 
group), a group of maternity service users convened by the University of Birmingham were involved in 
reviewing the participant information and were represented on the Trial Steering Committee. 
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Results 
Between 13
th 
May 2014 and 2
nd 
September 2016, 201 women were randomised to remifentanil PCA and 200 to 
pethidine.  Figure 1 shows the trial profile. 186 women received the allocated drug, in compliance with the 
protocol, in the remifentanil group and 154 in the pethidine group.  The main reasons for not receiving the 
allocated drug was women giving birth before it could be administered (n= 12 for remifentanil and 17 for 
pethidine) or a maternal decision to immediately request an epidural after randomisation, without receiving the 
allocated opioid, which only occurred in the pethidine group (n=22).  Participants had a mean age of 29·3 years 
and 60% were nulliparous. Table 1 provides more details of participant characteristics. 
Figure 1 Trial profile 
Table 1 Baseline characteristics of trial participants 
Primary outcome 
In the remifentanil group, 39 of 201 women (19%) had an epidural, compared to 81 of 199 (41%) women in the 
pethidine group, giving a risk ratio of 0·48 (95% CI 0·34 to 0·66, p<0·0001) in the unadjusted intention to treat 
analysis. Adjustment for the minimisation variables did not alter the risk ratio or its confidence intervals (Web 
table 1).  The sensitivity analysis, which excluded participants non-adherent to the study protocol, had little 
effect on the magnitude of the difference shown in the unadjusted analysis: 36/186 women (19%) in the 
remifentanil group had an epidural compared to 56/152 women (37%) in the pethidine group with a risk ratio of 
0·53 (95% CI 0·37-0·75, p<0·0003).  Sensitivity analysis grouping participants by the analgesia ultimately 
received similarly demonstrated little effect (Web Table 2). In the pre-specified subgroup analysis, no 
interaction was found between parity and the treatment effect; 30/121 (25%) nulliparous women in the 
remifentanil group and 58/118 (49%) women in the pethidine group received an epidural, as did 9/80 (11%) and 
23/81 (28%) parous women, respectively.  
Secondary outcomes: Maternal (Table 2) 
Median pain score was significantly reduced by 13·91 points (VAS Scale 0=No Pain, 100 = Worst Pain 
imaginable) in the remifentanil PCA, relative to the pethidine group (95% CI -21·40 to -6·43; p=0·0003) but 
there was no difference in maximum pain score between groups (mean difference -4·44 points; 95% CI -10·93 
to 2·05: p=0·18). (Table 2) 
The maternal outcomes of respiratory depression, defined as a maternal respiratory rate of <8 breaths per minute 
and excessive sedation, defined as not rousable by voice, did not differ between groups and were rare 
(respiratory depression: one in remifentanil; excessive sedation: two in remifentanil and three in pethidine 
group).  Significantly more women in the remifentanil group had low maternal oxygen saturation (<94% whilst 
breathing room air) compared to the pethidine group, 26/191 (14%) vs 8/169 (5%) respectively, RR 2·65 (95% 
CI 1·23-5·68, p=0·007).  Women randomised to remifentanil were more likely to receive supplemental oxygen 
than women in the pethidine group (Table 2). Significantly more women were given an anti-emetic in the 
pethidine than in the remifentanil group. 
With regard to delivery mode, the intervention significantly reduced the number of instrumental vaginal 
deliveries, with 52 (26%) in the pethidine group and 31(15%) in the remifentanil group, with equal proportions 
of Caesarean section in both groups (Table 2).  Interventional delivery for foetal distress was required for 
significantly fewer women in the remifentanil group 29/201(14%), compared to 51/199 (26%) who received 
pethidine (RR 0.56, 95% CI 0.37 to 0.85; p=0.005).  
Secondary outcomes: Neonatal (Table 3)  
All neonates had an Apgar score of ≥4 at five minutes after birth.  There was no difference between groups in 
Apgar score <7 at 5 minutes after birth or the rate of foetal acidosis (Table 3). There were 20 (10%) infants born 
to women in the remifentanil group and 21 (11%) infants of women in the pethidine group who required 
resuscitation (RR 0·94, 95% CI 0·53 to 1·68; p=0·84), predominantly with supplemental oxygen, although one 
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baby in the pethidine group required complex resuscitation. There was no difference in the rate of neonatal 
transfer to a higher level of neonatal care between study groups. 
There was no difference in the proportion of women successfully initiating breastfeeding within an hour of birth 
between groups.  Maternal satisfaction with their birth experience was assessed in nine domains and differences 
were found for two of these: more women in the remifentanil group agreed that their pain relief was effective 
and more agreed that they were satisfied with their pain relief than in the pethidine group (p=0.0003 in both 
cases).  (Table 4). 
The definition of expected, but unrelated adverse events was agreed at the outset of the trial, e.g. complications 
of labour and delivery, and as such could not be attributable to study interventions.  Adverse events of concern 
were defined as secondary outcomes, to be formally compared.  There were no serious adverse events or drug 
reactions directly attributable to either analgesic recorded during the study. 
Discussion 
This multicentre randomised controlled trial has demonstrated that intravenous remifentanil PCA for pain relief 
in labour substantially reduced progression to epidural analgesia, in comparison to intramuscular pethidine.  
Women receiving remifentanil were more likely to have a spontaneous vaginal delivery, with the difference in 
delivery mode attributable to a reduction in instrumental vaginal delivery. An increased rate of low maternal 
oxygen saturation was observed with remifentanil in comparison to pethidine and an additional requirement for 
oxygen supplementation, however it did not result in adverse maternal or neonatal sequelae.   
The strengths of our study include robust trial methodology, secure randomisation, rigorous analysis and 
transparent reporting. We recruited to target, achieved comparability at baseline, had independent data 
monitoring throughout and minimal patient or data loss, with the primary outcome available for all but one trial 
participant.  All outcome comparisons were pre-specified, with the exception of dichotomisation of 5 minute 
Apgar score at <7 which was requested during the review process of this report.  The diversity of our population 
across many centres adds to generalisability of the findings. Women with induced labour were somewhat over-
represented in the study population, although there was balance for this variable across the trial arms.  This 
reflects the time available for the consent and randomisation processes to be completed.  Women with induced 
labour were often admitted in advance of labour and therefore there was greater opportunity for providing trial 
information prior to consent in active labour.  Induction of labour is a very common procedure therefore our 
findings are relevant to a routine clinical population, given the very wide inclusion criteria for the study. 
There was a disparity in compliance to allocated treatment between remifentanil PCA and pethidine groups. 
Twenty- two women, randomised to pethidine, requested immediate progression to epidural, and three had an 
epidural placed for medical indications, without pethidine being administered.  The non-adherent women in the 
pethidine group most likely represent participants with an undisclosed preference for remifentanil or women 
with pre-conceptions regarding pethidine, who nonetheless consented to randomisation.  Episodes of non-
adherence were distributed across study centres and no systematic pattern was identified by monitoring.  The 
study protocol did not formally allow women to decline the analgesia to which they were randomised and opt 
immediately for epidural.  However, once a woman made a request for epidural analgesia, it could not ethically 
be denied, even if the request was made before the analgesia allocated by randomisation had been administered.   
Whilst the main unadjusted analysis of the primary outcome adhered to intention-to treat principles and included 
all participants randomised, regardless of the analgesia actually received, the difference in compliance between 
groups raised the possibility that observed treatment effects could potentially have been distorted by the 
disparity in adherence. However, when these episodes of non-adherence were excluded, analysis of women only 
deemed compliant with the randomised allocation yielded almost identical results both in the direction and 
magnitude of treatment effect, confirming that the intention to treat analysis was robust to the outcomes of non-
adherent participants.  Thus the observed benefits of remifentanil cannot be attributed to the difference in 
compliance between groups.  
A potential weakness of the study was the inability to mask clinical staff and women to the treatment allocation, 
made inevitable by the dissimilar technical aspects of intravenous PCA and intramuscular injection.  Blinding 
trial participants and clinical staff to the group allocation was impossible without the use of a “double dummy” 
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design and “sham” interventions, which would have included intravenous PCA with an inactive placebo and an 
inactive intra-muscular injection.  These possibilities were explored thoroughly at the study design stage.  Sham 
interventions were ultimately rejected as a result of strongly negative opinions expressed by women in the 
Patient and Public Involvement group assisting in study design.  Clinical staff were also unwilling to administer 
inactive, invasive procedures required for sham intervention or control.  The matter was explored at the stage of 
ethical approval with similarly unfavourable opinion from both medical and lay representatives.  Even if a 
“sham” design had been pursued, it may well not have been effective, since in practice it was found that women 
receiving remifentanil PCA immediately became aware of its effect, after a single intravenous bolus, therefore 
their group allocation would have been immediately obvious.  The limitations of an “open label” study design in 
terms of potential for performance or ascertainment bias were mitigated by precluding research staff from any 
involvement in the request for or decision to proceed to epidural, or any additional or subsequent clinical care of 
mother and baby, after randomisation. These methodological features should strengthen confidence that our 
findings are valid and reliable. 
The remifentanil PCA dose regimen was chosen carefully to reflect the one most commonly used in current 
practice in the UK.  A fixed remifentanil bolus dose, as opposed to a variable dose (i.e. dependent on maternal 
weight), was chosen to assist the ease of deployment of a pragmatic trial across multiple recruiting sites.  It is 
feasible that other doses regimens could cause different treatment effects.  However, most units adopting 
remifentanil PCA into practice opt for a fixed dose regimen for clarity and continuity.  The trials to date that 
have investigated the effectiveness of remifentanil relative to pethidine have been inconclusive as a result of 
inadequate size and quality.  A review by Schnabel included 244 participants in four studies, all judged to be of 
low or poor quality with a relative risk of progression to epidural of 0·34 (95% CI 0·2-0·58) for remifentanil 
compared to pethidine administered by any route
11
.  The relevant Cochrane review published in 2017 compared 
remifentanil PCA with a range of other analgesic regimes and stratified its meta-analyses according to the route 
of pethidine administration IM/IV or by PCA
13
. Three studies comprising 190 participants for the requirement 
for “escape” analgesia showed a risk ratio of 0·57 for remifentanil compared to IM/IV pethidine (95% CI 0·4-
0·81) and three studies of 215 participants showed a risk ratio of 0·76 (95% CI 0·45 to 1·28) for pethidine PCA.  
None of the studies included in these reviews were designed to examine epidural conversion as a primary 
outcome and in all but one study the outcome of escape analgesia was epidural.  Since the Cochrane review 
concluded that the evidence was too low in quality to inform practice or future research, the findings from our 
study therefore represent the first robust evidence that remifentanil reduces the requirement for epidural 
analgesia, compared to pethidine. 
Our study has demonstrated an effect on mode of delivery, showing that remifentanil PCA resulted in a 
significant reduction in instrumental vaginal delivery, relative to pethidine. Previous studies included in the 
Cochrane review have not shown an impact of remifentanil PCA on IVD rates compared with IM or IV 
pethidine (RR 0·82, 95% CI 0·32 to 2·09) (18). Mode of delivery was a secondary outcome in our trial, however 
the treatment effect was marked. Adding RESPITE to this previous meta-analysis shows a statistically 
significant reduction in IVD rate (RR 0·62, 95% CI 0·43 to 0·90; I
2
=0%).  Given that IVD increases the risk of 
perineal trauma and the morbidity it causes, remifentanil PCA could indirectly reduce long term side effects 
from instrumental delivery, including faecal incontinence and sexual dysfunction after childbirth, if it were used 
in preference to pethidine. 
Women who received remifentanil reported lower mean pain scores in labour and greater satisfaction with their 
pain relief in comparison to pethidine.  These results are in keeping with other studies in the field and set in the 
context that no policy of opioid analgesia in labour is as effective as epidural pain relief.  VAS data were 
incomplete since they were not always recorded contemporaneously by attending staff and could not be 
retrieved retrospectively.  VAS were seldom returned for women who delivered before receiving study drugs. 
Since pain scores were discontinued at epidural placement, none were recorded for women in the Pethidine 
group, who requested epidural immediately after randomisation, accounting for the imbalance in missing 
denominator values between trial arms. A lower rate of anti-emetic administration was also found with 
remifentanil, however, it was the practice of some participating centres to give an anti-emetic routinely with 
pethidine, so this finding should be interpreted with caution. 
Remifentanil, like any potent opioid, has the capacity to induce sedation and respiratory depression. Some units, 
who have adopted remifentanil for routine use in labour, uniformly administer oxygen to women using 
remifentanil PCA. Anxiety amongst some clinicians regarding the potential for serious adverse maternal 
respiratory side effects, including desaturation and apnoea has limited the widespread uptake of remifentanil 
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into routine practice
12
.  We recorded a single episode of low respiratory rate (less than 8 breaths per minute) in 
the remifentanil group. Excessive sedation was similarly rare and equally distributed between remifentanil and 
pethidine (two and three cases respectively). Predictably, there was a greater incidence of low oxygen saturation 
when breathing room air with remifentanil and supplemental oxygen use far more likely.   At trial inception, we 
made an active decision not to give supplemental oxygen uniformly with remifentanil, as some units using it 
choose to do, since not all women would ultimately require it, indeed 59% of the study population did not.  
From the outset of the study, supplementary oxygen use was recorded as “facial Oxygen to treat low oxygen 
saturation”.  On the advice of the DMC, at interim review, the precise indication for oxygen administration was 
collected in the last 152 women recruited to the study.  The data for these participants recorded whether 
supplementary oxygen was used (yes/no) and if yes, an indication was identified.  These two sets of data could 
not subsequently be combined and have therefore been reported alongside each other.  The predominant 
indication for supplemental oxygen was low maternal oxygen saturation.  The threshold for oxygen 
supplementation was a maternal saturation of less than 94% whilst breathing room air.  The use of maternal 
oxygen supplementation far exceeded the rate of low saturation and probably represents caution on the part of 
clinical staff.   
It was a goal of the study to generate reliable evidence for the maternal effects of pethidine and remifentanil 
PCA in the study population. Respiratory rate, sedation score and oxygen saturation were the principal 
observations used to evaluate opioid side effects and “one to one” midwifery care of participants was 
maintained throughout the study. End tidal carbon dioxide monitoring to detect apnoea is not routinely available 
in labour wards. The study sample size was calculated to detect differences in epidural conversion rather than 
potentially rarer safety outcomes.  Despite the reassuring absence of negative sequelae on mothers or neonates, 
larger populations would be required to establish their true prevalence.  
This study has answered the call for an adequately powered, robust, rigorously conducted, controlled trial to 
evaluate the effectiveness of remifentanil PCA in labour.  The benefits of remifentanil were a halving of the 
epidural rate relative to pethidine, the provision of superior pain relief and a reduction in instrumental delivery. 
Maternal respiratory side-effects of remifentanil did not occur in all women. When they did occur, they were 
transient, quickly identified, easily managed and did not impact on maternal or neonatal well-being. The 
evidence generated by this trial challenges the role of pethidine as a usual standard of care for women in 
childbirth and requires a fundamental re-evaluation of opioid pain relief in labour. 
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Figure 2: Trial Profile 
  
401 randomised  
2950 women eligible at start of labour 
1797 declined participation 
752 not randomised (no request for 
opioid analgesia, consented but 
not randomised etc) 
201 assigned remifentanil patient-
controlled analgesia 
200 assigned to pethidine  
154 received ≥1 100mg dose of 
pethidine 
186 received ≥1 40µg dose of 
remifentanil 
199 included in intention-to-treat 
population 
201 included in intention-to-treat 
population 
45 did not receive pethidine 
22 requested epidural 
17 delivered before pethidine 
administered 
4 pethidine not administered due to 
change in maternal condition 
1 declined pethidine, received 
remifentanil 
1 epidural administered under 
medical direction 
1 withdrew consent to use data  
14 did not receive remifentanil 
12 delivered before remifentanil 
administered 
2 declined remifentanil, received 
nitrous oxide/ oxygen 
1 not documented if remifentanil 
administered 
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Table 2: Patient Characteristics 
 Remifentanil 
(N=201) 
Pethidine 
(N=199) 
Patient Characteristics 
Age At Randomisation  
Mean (SD) years 29.4 (6.1) 29.3 (6.1) 
<20 years 12 (6%) 13 (7%) 
20–29 years 99 (49%) 97 (49%) 
30–39 years 80 (40%) 80 (40%) 
≥40years  10 (5%) 9 (4%) 
Ethnicity  
White 146 (73%) 157 (79%) 
Black/Black British 8 (4%) 7 (3%) 
Chinese/East Asian 4 (2%) 0 (-) 
Asian (Indian) 7 (4%) 12 (6%) 
Asian (Pakistani) 23 (11%) 17 (9%) 
Asian (Bangladeshi) 1 (1%) 1 (1%) 
Mixed 3 (1%) 0 (-) 
Other 9 (4%) 5 (2%) 
   
Weight (kg)                                     
Mean (SD, N) 73.1 (18.4,194) 74.0(17.2, 192) 
Range 45-147 38-125 
 
Obstetric History 
Gravidity 
Median [IQR] 2 [1-3] 2 [1-3] 
Parity 
Median [IQR] 0 [0-1] 0 [0-1] 
Nulliparous 121 (60%) 118 (59%) 
Previous Delivery Modes 
Unassisted vaginal  58 (74%) 50 (63%) 
Instrumental vaginal 14 (18%) 19 (24%) 
Elective caesarean section 7 (9%) 2 (3%) 
Emergency caesarean section 12 (15%) 15 (19%) 
Current pregnancy 
 
Induced 137 (68%) 136 (68%) 
Pre-eclampsia 8 (4%) 8 (4%) 
Continuous electronic fetal monitoring 188 (94%) 184 (92%) 
Syntocinon commenced before randomisation 100 (50%) 103 (52%) 
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Table 2: Maternal secondary outcomes  
 
 Remifentanil 
(N=201) 
Pethidine 
(N=199) 
Estimate  
(95% C.I) 
p-value 
Mode of birth 
Spontaneous vaginal 128 (64%) 106 (53%) 
- 0.02 Instrumental (forceps or suction) 31 (15%) 52 (26%) 
Caesarean section 42 (21%) 41 (21%) 
Supplementary oxygen 
Facial oxygen, to treat low saturation 
Yes 51/125 (41%) 1/119 (1%) 48.55¹ 
(6.82, 345.76) 
<0.001 
No 74/125 (59%) 118/119 (99%) 
Missing 0 4 - - 
Supplementary oxygen 
Yes 35/76 (46%) 1/76 (1%) 35.00¹ 
(4.92, 249.02) 
<0.001 
No 41/76 (54%) 75/76 (99%) 
Reasons for supplementary oxygen⁴ 
Low oxygen saturation 31/76 (89%) 1/1 (100%) 
- - 
Maternal sedation score (≥4) 0 (-) 0 (-) 
Physician request 6/76 (17%) 0 (-) 
Low respiration rate (<8 breaths/minute) 1/76 (3%) 0 (-) 
Other 0 (-) 0 (-) 
Pain scores 
Maximum VAS score⁵ 
Mean (SD, N) 75.90 (27.09, 150) 80.34 (26.24, 117) -4.44²  
(-10.93, 2.05) 
0.18 
Range 0-100 0-100 
Median VAS score⁵ 
Mean (SD, N) 50.67 (29.41, 150) 64.58 (32.57, 117) -13.91²  
(-21.40, -6.43) 
<0.001 
Range 0-100 0-100 
Respiratory depression (<8 breaths/minute) 
Yes 1 (1%) 0 (-) 
- 1.00 
No 186 (99%) 152 (100%) 
Missing 14 47 - - 
Low oxygen saturation (<94% whilst breathing room air) 
Yes 26 (14%) 8 (5%) 2.65¹  
(1.23, 5.68) 
0.007 
No 163 (86%) 146 (95%) 
Missing 12 45 - - 
Excessive sedation (≥4)⁶ 
Yes 2 (1%) 3 (2%) 0.54¹  
(0.09, 3.20) 
0.49 
No 185 (99%) 149 (98%) 
Missing 14 47 - - 
Anti-emetic administration 
Yes 42 (21%) 134 (68%) 0.31¹  
(0.23, 0.41) 
<0.0001 
No 159 (79%) 64 (32%) 
Missing 0 1 - - 
Breast feeding within first hour of birth 
Yes 90 (46%) 91 (47%) 0.99³  0.92 
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No 105 (54%) 104 (53%) (0.80, 1.22) 
Missing 6 4 - - 
¹Risk ratio, values <1 favour remifentanil. 
²Mean difference, values <0 favour remifentanil.  
³ Risk ratio, values >1 favour remifentanil. 
⁴Two participants in the Remifentanil arm selected both physician request and low oxygen saturation as the reason for supplemental 
oxygen. One participant in the Remifentanil arm selected both low respiratory rate and low oxygen saturation as the reason for 
supplemental oxygen. 
⁵VAS score ranges from 0-100, where 0=no pain, 100=worst pain imaginable. 
⁶Sedation scores range from 1-5 where 1=fully awake and 5=eyes closed and not rousable. 
 Missing data has been removed from denominators to generate % values 
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Table 3: Neonatal secondary outcomes  
 
 Remifentanil 
(N=201) 
Pethidine 
(N=199) 
Estimate  
(95% C.I) 
p-value 
Apgar 
Apgar Score <4 
<4 0 (-) 0 (-) 
- - 
≥4 201 (100%) 199 (100%) 
Apgar Score <7 
<7 1 (1%) 2 (1%) 0.50¹  
(0.05, 5.42) 
0.56 
≥7 200 (99%) 197 (99%) 
Fetal Acidosis 
Umbilical Cord pH 
Mean (SD, N) 7.24 (0.09, 91) 7.24 (0.09, 97) 
- - 
Range 6.89 – 7.42 6.98 – 7.39 
Base Deficit (mmol/l) 
Mean (SD, N) -2.93 (5.21, 88) -2.69 (5.33, 97) 
- - 
Range -18.90 – 7.50 -12.30 – 9.70 
Fetal Acidosis 
Yes 2 (2%) 1 (1%) 2.18¹ 
(0.20, 23.64) 
0.51 
No 86 (98%) 95 (99%) 
Missing 113 103 - - 
Admission to Higher Level Care 
Yes 8 (4%) 9 (5%) 0.88¹  
(0.35, 2.23) 
0.79 
No 193 (96%) 190 (95%) 
Requirement for Neonatal Resuscitation 
Yes 20 (10%) 21 (11%) 0.94¹  
(0.53, 1.68) 
0.84 
No 181 (90%) 178 (89%) 
Interventional delivery for foetal distress 
Yes 29 (14%) 51 (26%) 0.56 
(0.37, 0.85) 
0.005 
No 172 (86%) 148 (74%) 
¹Risk ratio, values <1 favour remifentanil.  
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Table 4: Maternal satisfaction 
 
 Remifentanil 
(N=184) 
Pethidine 
(N=176) 
p-value 
1: I was satisfied with my overall childbirth experience 
Strongly disagree 4 (2%) 1 (1%) 
0.27 
Disagree 10 (6%) 8 (5%) 
Neutral 17 (9%) 11 (6%) 
Agree 66 (36%) 71 (40%) 
Strongly agree 87 (47%) 85 (48%) 
2: I was treated with respect by all of the staff 
Strongly disagree 1 (1%) 1 (1%) 
0.21 
Disagree 0 (-) 1 (1%) 
Neutral 7 (4%) 2 (1%) 
Agree 26 (14%) 18 (10%) 
Strongly agree 150 (81%) 154 (87%) 
3: I was involved in making decisions as much as I wanted to be 
Strongly disagree 1 (1%) 1 (1%) 
0.19 
Disagree 3 (2%) 2 (1%) 
Neutral 10 (5%) 2 (1%) 
Agree 39 (21%) 39 (22%) 
Strongly agree 131 (71%) 132 (75%) 
4: My expectations for labour and birth were met 
Strongly disagree 8 (4%) 5 (3%) 
0.68 
Disagree 13 (7%) 13 (7%) 
Neutral 27 (15%) 33 (19%) 
Agree 50 (27%) 51 (29%) 
Strongly agree 86 (47%) 74 (42%) 
5: I felt safe at all times 
Strongly disagree 1 (1%) 2 (1%) 
0.41 
Disagree 6 (3%) 1 (1%) 
Neutral 6 (3%) 4 (2%) 
Agree 35 (19%) 35 (20%) 
Strongly agree 136 (74%) 134 (76%) 
6: Good communication from the staff kept me well informed 
Strongly disagree 0 (-) 1 (1%) 
0.87 
Disagree 1 (1%) 0 (-) 
Neutral 6 (3%) 5 (3%) 
Agree 37 (20%) 32 (18%) 
Strongly agree 140 (76%) 138 (78%) 
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Remifentanil 
(N=184) 
Pethidine 
(N=176) 
p-value 
7: I felt in control 
Strongly disagree 6 (3%) 4 (2%) 
0.52 
Disagree 8 (4%) 12 (7%) 
Neutral 30 (16%) 35 (20%) 
Agree 62 (34%) 54 (31%) 
Strongly agree 77 (42%) 71 (40%) 
Missing 1 (1%) 0 (-) - 
8: My pain relief was effective during labour 
Strongly disagree 4 (2%) 4 (2%) 
0.0003 
Disagree 9 (5%) 14 (8%) 
Neutral 12 (7%) 33 (19%) 
Agree 50 (27%) 57 (32%) 
Strongly agree 109 (59%) 68 (39%) 
9: I was satisfied with my labour pain relief 
Strongly disagree 3 (2%) 6 (4%) 
0.0003 
Disagree 9 (5%) 13 (7%) 
Neutral 11 (6%) 23 (13%) 
Agree 44 (24%) 60 (34%) 
Strongly agree 117 (63%) 74 (42%) 
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Supplementary Information 
 
Adjusted and sensitivity analyses of primary outcome 
 
In addition to the primary unadjusted ITT analysis of the primary outcome, a further log-binomial model was fitted, 
adjusting for the minimisation variables:  
 
 Ethnicity (south Asian, Other) 
 Age (<20, 20-29, 30-39, ≥40 years) 
 Parity (nulliparous, multiparous) 
 Type of labour (induced, spontaneous) 
 
Table 3: Primary adjusted intention to treat analysis 
 Remifentanil 
(N=201) 
Pethidine 
(N=199) 
Risk Ratio¹ 
(95% C.I) 
p-value 
Woman received epidural 
Yes 39 (19%) 81 (41%) 
0.47 (0.34, 0.65) <0.0001 
No 162 (81%) 118 (59%) 
¹Remifentanil vs. Pethidine (values <1 favour Remifentanil). 
 
 
Two ‘per-protocol’ analyses were undertaken for the primary outcome as sensitivity analyses to explore the potential 
effect of: 
 
I. Non-adherence to the randomised allocation. The ‘per-protocol’ cohort was defined as only including those 
participants who complied with allocation and received only the randomised allocation. In the pethidine 
group, 45 women did not receive any pethidine and two participants received both pethidine and 
remifentanil. In the remifentanil group, 14 women did not receive any remifentanil and for one participant, it 
was not documented whether or not they received remifentanil and hence was excluded from this analysis. 
Results are reported in the main text. 
 
II. Cross-over between treatment groups. Participants were grouped according to the intervention they 
ultimately received rather than the intervention to which they were randomised. Excluded from the analysis 
were 44 participants who did not receive their allocated pethidine, 13 participants who did not receive 
remifentanil, and the single participant for whom it was not documented whether they received their 
allocated remifentanil. Two participants in the pethidine group received pethidine and then went on to 
receive remifentanil, so are considered in the remifentanil group. One participant in the remifentanil group 
received only pethidine, and conversely one participant in the pethidine arm received only remifentanil. 
Results are in Table 4. 
 
 
Table 4: Per-protocol sensitivity analysis: cross-over between treatment groups 
 
 Remifentanil 
(N=189) 
Pethidine 
(N=153) 
Risk Ratio¹ 
(95% C.I) 
p-value 
Woman received epidural 
Yes 37 (20%) 57 (37%) 
0.53 (0.37, 0.75) 0.0003 
No 152 (80%) 96 (63%) 
¹Remifentanil vs. Pethidine (values <1 favour Remifentanil
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